中文

Hong Kong Stocks · Free Data Page

CHINARES PHARMA 03320

CHINARES PHARMA: FY2025 revenue CN¥269.6B (+4.60% YoY); net income CN¥4.05B; 2 alerts, 1 watch item out of 17 risk checks; TTM dividend HK$0.24/sh.
Close PriceHK$4.68Day -0.11%Market CapHK$29.43BP/E6.2xTTMP/B0.48xDividend Yield5.11%TTMROE (FY2025)8.1%Avg. equity

Prices are closing data as of 2026-11-04, not real-time quotes. HK P/E and P/B multiples come from Eastmoney HK key statistics. Metric definitions: P/E, P/B, ROE.

Want the full AI research report for CHINARES PHARMA?

This free page compiles public filings, financial ratios and risk screening. Generate a full research report to add business moat & competition, valuation scenarios, catalysts and bull/bear cases right at this URL.

New users who sign up free and verify their email receive 2 free credits for research reports or professional valuation.

10-Year FinancialsFY2016–2025

Financial statements are reported in CNY, while share price and market cap are quoted in HKD.

Key Multi-Year Facts

  • Revenue moved from CN¥156.7B in FY2016 to CN¥269.6B in FY2025 (9-year CAGR +6.2%).
  • Profitable in every fiscal year across 2016–2025.

Latest 5 Fiscal Years

Fiscal Year20212022202320242025
Revenue (CNY B)237218245258270
YoY18.2%-7.9%12.2%5.3%4.6%
Net Income (CNY B)3.773.503.853.354.05
YoY14.3%-7.1%10.1%-13.1%20.7%
Operating Cash Flow (CNY B)10.510.815.517.520.5
ROE8.6%8.2%8.6%7.1%8.1%
Gross Margin14.9%15.4%15.7%15.8%16.5%
Net Margin1.6%1.6%1.6%1.3%1.5%
Debt-to-Assets61.8%62.6%62.3%61.9%58.9%
Show all 10 fiscal years
Fiscal Year2016201720182019202020212022202320242025
Revenue (CNY B)157173190204200237218245258270
YoY—10.1%9.9%7.8%-2.0%18.2%-7.9%12.2%5.3%4.6%
Net Income (CNY B)2.823.483.983.293.303.773.503.853.354.05
YoY—23.5%14.2%-17.4%0.3%14.3%-7.1%10.1%-13.1%20.7%
Operating Cash Flow (CNY B)3.694.067.237.296.9110.510.815.517.520.5
ROE7.5%8.8%9.8%8.2%7.6%8.6%8.2%8.6%7.1%8.1%
Gross Margin15.4%16.4%18.4%16.6%16.1%14.9%15.4%15.7%15.8%16.5%
Net Margin1.8%2.0%2.1%1.6%1.6%1.6%1.6%1.6%1.3%1.5%
Debt-to-Assets59.5%60.7%65.7%63.4%61.8%61.8%62.6%62.3%61.9%58.9%

Fiscal years follow the period-end calendar year (hover headers for period-end dates). ROE uses average beginning/ending equity. Source: HKEX / Eastmoney financial statements, compiled mechanically without AI. Official filings

Risk ChecklistAs of 2026-11-05

Rules-based screening using HK financial statements and HKEX announcement categories (no AI opinions).

2Alert 1Watch 14Pass

Items Flagged for Review

  • Alert

    GoodwillFinancial Quality

    CN¥24.35B, 46.1% of equity

    Interim (2026-06-30) · What is this?

  • Alert

    Short-Term Debt CoverageSolvency

    Cash CN¥15.62B, short-term debt CN¥52.93B (0.30x)

    Interim (2026-06-30) · What is this?

  • Watch

    Profit WarningMaterial Events

An "Alert" or "Watch" item flags a number that merits verification in primary filings, not a sell signal.

Dividends

Trailing 12-month dividend: HK$0.240 per share, or 5.11% yield at closing price; last full fiscal year: HK$0.218 (payout ratio 31.7%).

Figures are gross HKD per share before applicable withholding or Stock Connect dividend taxes.

More data: All research reports · Sector leaders · Market hours & holidays.

Compiled mechanically from public filings and market quotes (data as of 2026-11-05). For informational purposes only, not investment advice.